Is Teva Pharmaceutical Industries Limited (TEVA) a Buy, Sell, or Hold?
Teva Pharmaceutical Industries Limited
NYSE:TEVA
$31.82 USD
-$0.36 (-1.12%)
- Volume
- 3.45M
- Average Volume
- 6.31M
- Market Capitalization
- $37.05B
- P/E Ratio
- 23.15
- Dividend Yield
- 0.00%
- Price Target
- $41.00
- Year High
- $37.35
- Year Low
- $14.99
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.01
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Richard D. Francis |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Current Symbol | TEVA |
| CUSIP | 881624209 |
| CIK | 0000818686 |
| Web | https://www.tevapharm.com |
| Phone | 972 3 914 8213 |
| Currency | USD |
| Employees | 37000 |
| Country | IL |
Liquidity
| Debt-to-Equity Ratio | 2.05 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.01 |
| Quick Ratio | 0.78 |
| Cash Ratio | 0.28 |
Sales & Book Value
| Annual Sales | $17.26B |
| Price / Sales | 2.13 |
| Cash Flow | 1.64 |
| Price / Cash Flow | 19.66 |
| Price / Book | 4.45 |
Price Target and Rating
| Average Stock Price Forecast | $41.00 |
| High Stock Price Forecast | $42.00 |
| Low Stock Price Forecast | $40.00 |
| Forecast Upside/Downside | -22.39% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 46 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $1.2 |
| Trailing P/E Ratio | 23.15 |
| PEG Ratio | 0.01 |
| P/E Growth | 0.01 |
| Net Income | $1.41B |
| Net Margin | 9.03% |
| Pretax Margin | 7.92% |
| Return on Equity | 20.79% |
| Return on Assets | 3.90% |
Financials Score
| AltmanZ Score | 0.86 |
| Piotroski Score | 7.00 |
| Working Capital | 178M |
| Total Assets | 40.04B |
| Ebit | 2.27B |
| Market Cap | 36.99B |
| Total Liabilities | 31.81B |
Poll Results
About Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In t ... he central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study
2026-07-12 18:02:15
Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
2026-07-09 12:12:04
Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growth innovative assets.
2026-07-09 09:00:00
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG tod
2026-07-09 08:45:00
TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics' proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics' proven bios.
2026-07-09 08:30:00
Teva secures exclusive global rights to commercialize Polpharma Biologics' biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva's Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.
2026-07-08 18:47:32
In a recent interview, legendary investor Bill Ackman was asked about why he was bullish on the economy of Israel. The question comes with Ackman owning around a 5% stake in the Tel Aviv Stock Exchange.
2026-07-07 16:02:42
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
2026-07-06 13:09:01
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
Frequently Asked Questions
-
What is the current Teva Pharmaceutical Industries Limited (TEVA) stock price?
-
Teva Pharmaceutical Industries Limited(NYSE:TEVA) stock price is $31.82 in the last trading session. During the trading session, TEVA stock reached the peak price of $37.35 while $14.99 was the lowest point it dropped to. The percentage change in TEVA stock occurred in the recent session was --1.12% while the dollar amount for the price change in TEVA stock was -$-0.36.
-
TEVA's industry and sector of operation?
-
The NYSE listed TEVA is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of TEVA?
-
Eric A. Hughes | Executive Vice President of Global R&D and Chief Medical Officer
Evan Lippman | Executive Vice President of Business Development
Richard Francis | President, Chief Executive Officer & Director
Christine Fox | Executive VP of US Commercial & Head of Innovative Franchise
Amir Weiss | Senior Vice President & Chief Accounting Officer -
How many employees does TEVA have?
-
Number of TEVA employees currently stands at 37000. TEVA operates from 124 Dvora Hanevi'a Street, Tel Aviv, TA 6944020, IL.
-
Link for TEVA official website?
-
Official Website of TEVA is: https://www.tevapharm.com
-
How do I contact TEVA?
-
TEVA could be contacted at phone #972 3 914 8213 and can also be accessed through its website. TEVA operates from 124 Dvora Hanevi'a Street, Tel Aviv, TA 6944020, IL.
-
How many shares of TEVA are traded daily?
-
The average number of TEVA shares traded daily for last 3 months was 6.31M.
-
What is the market cap of TEVA currently?
-
The market value of TEVA currently stands at $37.05B with its latest stock price at $31.82